A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy

Abstract

Abstract A double-blind, controlled, clinical trial of spironolactone (Aldactone-A), 50 mg. b. d., showed this to be better than a placebo for the short-term treatment of benign prostatic hypertrophy, although the advantage was not maintained over a longer period of time. There was considerable response to the placebo and the importance of comparative trials with objective measurements is discussed.